Verticals / Pharma, medtech & health distribution / VedaBio
V
VedaBio
94
Latest disclosed NPS
1 Sep 2026
1
NPS entries
1 with a number
2026
Years covered
1 entries in all
In their words
“VedaBio partner UCP Merchant Medicine reports Net Promoter Score of 94 against an industry average of 71.”
NPS disclosures (1)
1 Sep 2026
NPS94
VedaBio partner UCP Merchant Medicine reports Net Promoter Score of 94 against an industry average of 71.
— reported by biospace.com · 1 Sep 2026
biospace.com ↗Retention disclosures (0)
No retention figures yet.
Lighthouse companies in Pharma, medtech & health distribution
About these figures
Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.
NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.